

MITIGATION - SCIENCE AND TECHNOLOGY ADVANCES FOR CHEMICAL AND BIOLOGICAL HAZARD MITIGATION

Skinkast: A Multi-modal Dermal Disclosure Spray For The Rapid Detection Of Chemical Warfare Agents On Intact Skin

 Zachary Canter US Army Medical Research Institute of Chemical Defense
 Luke Richardson US Army Medical Research

 Institute of Chemical Defense (ORISE)
 Justin Sherlock US Army Medical Research Institute of Chemical Defense (ORISE)

 Rabia Ali US Army Medical Research Institute of Chemical Defense (ORISE)
 Noah Roberts US Army Medical Research Institute

 of Chemical Defense (ORISE)
 Thomas McClymont US Army Medical Research Institute of Chemical Defense (ORISE)
 Noah Roberts US Army Medical Research Institute

 of Chemical Defense (ORISE)
 Thomas McClymont US Army Medical Research Institute of Chemical Defense (ORISE)
 Robert

 diTargiani US Army Medical Research Institute of Chemical Defense
 Shane Kasten US Army Medical Research Institute of

 Chemical Defense
 Nicholas Paparoidamis US Army Medical Research Institute of Chemical Defense

FOCUS

276

Chemical warfare agents (CWAs) are not only extremely potent, but also in pure form often colorless and odorless, which can lead to undetectable dermal exposures without employing specialized analytical instrumentation. A subset of chemical warfare nerve agents (CWNAs), known as persistent agents, along with vesicants, synthetic opioids, and toxins all demand specialized care and attention following dermal exposure. If left untreated, morbidity and death are certain with severe exposures. At present, no dermal disclosure medical devices are available that can provide visual indication of exposure capable of directing decontamination technologies. A simple but rapid disclosure spray could decouple detection from lab-based instrumentation and specialized methods. SkinKast, a dermal disclosure spray-filming technology, is in early prototype development for detection of exposure to various CWAs on intact skin. The prototype formulation has been impregnated with three separate reagent systems to allow detection of CWNAs, vesicants, and synthetic opioids. Besides detection, SkinKast will potentially offer other modalities to include the initiation of chemical and physical decontamination along with extraction of the exposing substance or the neutralized product for lab-based identification. Prototype studies will be discussed from proof-of-concept to in vivo assessments conducted on porcine skin.

This research was supported in part by an appointment to the Department of Defense (DOD) Research Participation Program administered by the Oak Ridge Institute for Science and Education (ORISE) through an interagency agreement between the U.S. Department of Energy (DOE) and the DOD. ORISE is managed by ORAU under DOE contract number DE-SC0014664. All opinions expressed in this paper are the author's and do not necessarily reflect the policies and views of DOD, DOE, or ORAU/ORISE.

This work was supported by the Defense Threat Reduction Agency (DTRA), Research and Development Directorate, Chemical and Biological Technologies Department, Detection/Diagnostics Division under project number CB11038.